Market Research Logo

Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors

Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors Summary

Oncology comprises a large and diverse group of indications, encompassing virtually all sites and tissues in the human body. The diseases are characterized by abnormal cell proliferation, which is followed by local tissue invasion and, at an advanced stage of the disease, the migration of the cancer cells to other parts of the body. Cancer is a genetically driven disease, with iterative mutations providing selective advantages to the cells in the context of the specific tissue site, followed by clonal expansion.

Cancer is anticipated to become increasingly prevalent due to aging populations and rising levels of obesity in the developed world. Furthermore, the development and approval of more targeted oncology treatments is anticipated to decrease toxicity and increase chemotherapy usage in elderly patients. Targeted treatment administration will increase the overall survival of poor-performance-status patients (having impaired functional status) and enable more rounds of chemotherapy to be administered.

In 2012, there were 32.6 Million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages. In a typical course of therapy for cancer, multiple chemotherapy compounds are administered sequentially in combination regimens, as an adjunct to surgery and radiation therapy. Chemotherapy drugs are cytotoxic to dividing cells, meaning that they act on both healthy and malignant tissues and are fairly toxic.

There has been a shift towards developing targeted therapies, such as mAbs and cell therapies. Targeted therapies, by their nature, have less toxicity associated with their use and as a result can be administered to more cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive. The most commercially successful oncology treatments are mAbs such as MabThera/Rituxan, Avastin and Herceptin.

Key market players (as determined by the total oncology revenue), namely Roche, Celgene, Bristol Myers Squibbs and Novartis, are forecast to maintain their strong market shares throughout the forecast period. Nevertheless, despite the approaching patent expiries of Avastin, Kadcyla, Perjeta and Tarceva, Roche is expected to maintain the highest market share of any company.

The report “Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors” provides an introduction to oncology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications and prognosis. Methods of diagnosis are also provided.

In particular, this report provides the following analysis -

  • Provides an overview of the oncology marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the oncology pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: breast, colorectal, lung and prostate cancer. The clinical trial landscape is also examined, with an emphasis on trends in clinical trial failure rates, duration and size.
  • Presents forecast projections to 2023 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan.
  • Assesses the company landscape in oncology, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company’s pipeline portfolio and total revenue.
  • Analyzes trends in co-development and licensing deals relating to oncology products. Some of the most prominent deals are discussed in detail.
Scope
  • Global revenue for the oncology market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.66%, from $118.6 billion in 2016 to $241.0 billion in 2023. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
  • The oncology pipeline is large and fairly diverse and contains 7,773 products. How does the composition of the pipeline compare with that of the existing market? What are the most popular types of molecule type and molecular target in the pipeline?
  • What mechanisms of action and molecule types are most common for pipeline products being trialed in the various key indications?
  • How will the market shares and CAGRs of the top 20 pharma companies compare within oncology?
  • What proportion of the key players’ revenues will be attributable to oncology products?
Reasons to buy
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
  • Visualize the composition of the oncology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
  • Analyze the oncology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
  • Understand the growth in patient epidemiology and market revenue for the oncology market globally and across the key players and product types
  • Stratify the market in terms of the generic and premium product revenue split between oncology products and assess the role of these product types in the treatment of the various cancers
  • Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Therapy Area Introduction
    • Symptoms
      • Table Oncology, Global, Symptoms of Key Indication Cancers, 2017
    • Diagnosis
    • Etiology and Pathophysiology
      • Etiology
      • Pathophysiology
    • Co-morbidities and Complications
      • Table Complications Associated with Breast, Colorectal, Lung, Prostate and Hematological Cancers
    • Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
      • Table Oncology, Global, Epidemiology of Key Indication Cancers, 2017
      • Breast Cancer
        • Table Figure 1: Oncology, Major Markets, Treatment Usage Patterns for Breast Cancer, Patients (millions), 2016-2022
      • Colorectal Cancer
        • Table Figure 2: Oncology, Major Markets, Treatment Usage Patterns for Colorectal Cancer, Patients (`000), 2016-2023
      • Lung Cancer
        • Table Figure 3: Oncology, Major Markets, Treatment Usage Patterns for Lung Cancer, Patients (`000), 2016- 2023
      • Prostate Cancer
        • Table Figure 4: Oncology, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients (millions), 2016-2021
      • Hematological Cancers
        • Table Figure 5: Oncology, Major Markets, Treatment Usage Patterns for Hematological Cancer, Patients (`000), 2016-2023
    • Prognosis
      • Breast Cancer
        • Table Oncology Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017
      • Colorectal Cancer
        • Table Oncology Market, US, Colorectal Cancer Stage and Survival Rates (%), 2017
      • Non-Small-Cell Lung Cancer
        • Table Oncology Market, US, Lung Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017
      • Prostate Cancer
        • Table Oncology, US, Prostate Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017
    • Treatment
      • Surgery and Radiation Therapy
      • Chemotherapy
        • Table Optimal and Actual Chemotherapy Usage Rates, 2010
      • Hormonal Therapies
      • Targeted Therapies
  • Key Marketed Products
    • Overview
      • Table Figure 6: Oncology, Global, Key Marketed Products and Approved Indications, 2017
    • MabThera/Rituxan (rituximab)
      • Table Oncology Therapeutics Market, Global, Approved Indications for Rituxan, 2017
      • Table Figure 7: Oncology, Global, Annual Revenue for Rituxan ($bn), 2006-2023
    • Avastin (bevacizumab)
      • Table Oncology Therapeutics Market, Global, Approved Indications for Avastin, 2017
      • Table Figure 8: Oncology, Global, Annual Revenues for Avastin ($bn), 2006-2023
    • Herceptin (trastuzumab)
      • Table Oncology Therapeutics Market, Global, Approved Indications for Herceptin, 2017
      • Table Figure 9: Oncology, Global, Annual Revenues for Herceptin ($bn), 2006-2023
    • Revlimid (lenalidomide)
      • Table Oncology Therapeutics Market, Global, Approved Indications for Revlimid, 2017
      • Table Figure 10: Oncology, Global, Annual Revenue for Revlimid ($bn), 2006-2023
    • Opdivo (nivolumab)
      • Table Oncology Therapeutics Market, Global, Approved Indications for Opdivo, 2017
      • Table Figure 11: Oncology, Global, Annual Revenues for Opdivo ($bn), 2014-2023
    • Xtandi (enzalutamide)
      • Table Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2017
      • Table Figure 12: Oncology, Global, Annual Revenues for Xtandi ($bn), 2012-2023
    • Gleevec/Glivec (imatinib mesylate)
      • Table Oncology Therapeutics Market, Global, Approved Indications for Gleevec, 2017
      • Table Figure 13: Oncology, Global, Annual Revenues for Gleevec ($bn), 2006-2023
    • Alimta (pemetrexed)
      • Table Oncology Therapeutics Market, Global, Approved Indications for Alimta, 2017
      • Table Figure 14: Oncology, Global, Annual Revenues for Alimta ($bn), 2006-2023
    • Zytiga (abiraterone acetate)
      • Table Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2017
      • Table Figure 15: Oncology, Global, Annual Revenues for Zytiga ($bn), 2011-2023
    • Conclusion
  • Pipeline Landscape Assessment
    • Overview
      • Table Figure 16: Oncology, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
    • Pipeline Development Landscape
      • Table Figure 17: Oncology, Global, Pipeline for Oncology by Stage of Development, Molecule Type and Program Type, 2017
      • Table Figure 18: Oncology, Global, Pipeline for Key Oncology Indications by Stage of Development, 2017
      • Table Figure 19: Oncology, Global, Pipeline for Key Oncology Indications by Molecule Type, 2017
    • Molecular Targets in the Pipeline
      • Table Figure 20: Oncology, Global, Pipeline for Oncology by Molecular Target, 2017
      • Table Figure 21: Oncology, Pipeline by Mechanism of Action and Stage of Development, 2017
      • Table Figure 22: Oncology, Global, Pipeline for Key Oncology Indications by Molecular Target, 2017
    • Clinical Trials
      • Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 23: Oncology, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017
        • Table Figure 24: Oncology, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017
        • Table Figure 25: Oncology, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017
        • Table Figure 26: Oncology, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017
      • Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 27: Oncology, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
        • Table Figure 28: Oncology, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
        • Table Figure 29: Oncology, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017
        • Table Figure 30: Oncology, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017
      • Clinical Trial Size and Duration by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 31: Oncology, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017
        • Table Figure 32: Oncology, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017
        • Table Figure 33: Oncology, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017
        • Table Figure 34: Oncology, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017
      • Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 35: Oncology, Global, Clinical Program Size by Stage of Development (participants), 2006- 2017
        • Table Figure 36: Oncology, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2017
        • Table Figure 37: Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017
        • Table Figure 38: Oncology, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017
      • Conclusion
    • Assessment of Key Pipeline Products
      • Durvalumab - AstraZeneca
        • Table Figure 39: Oncology, Global, Revenue Forecast for Durvalumab ($bn), 2017-2023
      • Durvalumab and Tremelimumab - AstraZeneca
        • Table Figure 40: Oncology, Global, Revenue Forecast for Durvalumab + Tremelimumab ($bn), 2017-2023
      • Abemaciclib - Eli Lilly
        • Table Figure 41: Oncology, Global, Revenue Forecast for Abemaciclib ($bn), 2018-2023
      • Rova-T (rovalpituzumab tesirine) - AbbVie
        • Table Figure 42: Oncology, Global, Revenue Forecast for Rova-T ($bn), 2018-2023
      • Neratinib - Puma Biotechnology
        • Table Figure 43: Oncology, Global, Revenue Forecast for Neratinib ($bn), 2016-2023
      • Acalabrutinib - AstraZeneca
        • Table Figure 44: Oncology, Global, Revenue Forecast for Acalabrutinib ($bn), 2018-2023
      • KTE-C19 (Axicabtagene Ciloleucel) - Kite Pharma
        • Table Figure 45: Oncology, Global, Revenue Forecast for Axicabtagene Ciloleucel ($bn), 2017-2023
      • Tisagenlecleucel-T - Novartis
        • Table Figure 46: Oncology, Global, Revenue Forecast for Tisagenlecleucel-T ($bn), 2017-2023
      • Conclusion
  • Multi-scenario Market Forecast to 2023
    • Overall Market Size
      • Table Figure 47: Oncology, Global, Market Size ($bn), 2016-2023
      • Table Oncology, Global, Market Size ($bn), 2016-2023
    • Generic Penetration
      • Table Figure 48: Oncology, Global, Generic Penetration for Annual Revenue Forecasts ($bn), 2016-2023
      • Table Oncology, Global, Usage of Generics Across Key Indications, 2017
    • Revenue Forecast by Molecular Target
      • Programmed Cell Death Protein 1/Programmed Cell Death 1 Ligand 1
        • Table Figure 49: Oncology, Global, Annual Revenue Forecast for Programmed Cell Death Protein 1/ Programmed Cell Death 1 Ligand 1 ($bn), 2016-2023
      • Tumor Necrosis Factor
        • Table Figure 50: Oncology, Global, Annual Revenue Forecast for Tumor Necrosis Factor ($bn), 2016-2023
      • Tyrosine-Protein Kinase BTK
        • Table Figure 51: Oncology, Global, Annual Revenue Forecast for Tyrosine-Protein Kinase BTK ($bn), 2016-2023
      • Cyclin-Dependent Kinases
        • Table Figure 52: Oncology, Global, Annual Revenue Forecast for Cyclin-Dependent Kinases ($bn), 2016-2023
      • Androgen Receptor
        • Table Figure 53: Oncology, Global, Annual Revenue Forecast for Androgen Receptor ($bn), 2016-2023
      • Vascular Endothelial Growth Factor
        • Table Figure 54: Oncology, Global, Annual Revenue Forecast for Vascular Endothelial Growth Factor ($bn), 2016-2023
  • Company Analysis and Positioning
    • Table Figure 55: Oncology, Global, Companies by Type, Cluster by Growth and Market Share, 2016-2023
    • Table Figure 56: Oncology, Global, Company Analysis Matrix, 2017
    • Revenue and Market Share Analysis by Company
      • Table Oncology Therapeutics Market, Global, Forecast Revenues by Company, 2016-2023
      • Table Figure 57: Oncology, Global, Forecast Market Share by Company (%), 2016-2023
      • Table Figure 58: Oncology, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
      • Table Figure 59: Oncology, Global, Revenues by Product Type, 2016-2023
      • Roche - To What Extent Will Newly Approved and Pipeline Product Approvals Offset the Patent Expiries of Avastin and Herceptin?
        • Table Figure 60: Oncology, Global, Roche Oncology Annual Revenue Forecast ($bn), 2016-2023
      • Celgene - How Will Multiple Patent Expiries Affect Oncology-Related Revenues?
        • Table Figure 61: Oncology, Global, Celgene Annual Revenue Forecast ($bn), 2016-2023
      • Novartis - How Will Mekinist plus Tafinlar and Tasigna Perform over the Forecast Period?
        • Table Figure 62: Oncology, Global, Novartis AG Annual Revenue Forecast ($bn), 2016-2023
      • Bristol-Myers Squibb - How Successful Will Recent Approvals Opdivo and Empliciti Become?
        • Table Figure 63: Oncology, Global, Bristol-Myers Annual Revenue Forecast ($bn), 2016-2023
      • Pfizer - What Do Sutent and Inlyta Patent Expiries Mean for Pfizer?
        • Table Figure 64: Oncology, Global, Pfizer Annual Revenue Forecast ($bn), 2016-2023
      • AstraZeneca - How Will its Immune Checkpoint Inhibitors Durvalumab and Tremelimumab Perform?
        • Table Figure 65: Oncology, AstraZeneca Annual Revenue Forecast ($bn), 2016-2023
    • Company Landscape
      • Table Figure 66: Oncology, Global, Companies by Type, 2016-2023
    • Marketed and Pipeline Portfolio Analysis
      • Table Figure 67: Oncology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Oncology Specialization, 2016-2023
      • Table Figure 68: Oncology, Global, Proportion of Total Company Revenue Attributed to Cancer, 2016-2023
  • Strategic Consolidations
    • Licensing Deals
      • Deals by Region, Year and Value
        • Table Figure 69: Oncology, Global, Licensing Deals, 2006-2017
        • Table Figure 70: Oncology, Global, Licensing Deals by Indication and Value, 2006-2017
      • Deals by Stage of Development and Value
        • Table Figure 71: Oncology, Global, Licensing Deals by Volume and Value, 2006-2017
      • Deals by Molecule Type, Mechanism of Action and Value
        • Table Figure 72: Oncology, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2017
      • Table for Licensing Deals Valued Above $100m
        • Table Oncology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2017
    • Co-development Deals
      • Deals by Region, Year and Value
        • Table Figure 73: Oncology, Global, Co-development Deals, 2006-2017
        • Table Figure 74: Oncology, Global, Co-development Deals by Indication and Value, 2006-2017
      • Deals by Stage of Development and Value
        • Table Figure 75: Oncology, Global, Co-development Deals by Volume and Value, 2006-2017
      • Deals by Molecule Type, Mechanism of Action and Value
        • Table Figure 76: Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017
      • Table for Co-development Deals Valued $1 billion and Above
        • Table Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017
  • Appendix
    • References
      • Table Oncology, Global, All Pipeline Products, 2017
    • Abbreviations
      • Table Abbreviations
    • Methodology
      • Secondary Research
      • Market Size and Revenue Forecasts
      • Pipeline Analysis
      • Competitive Landscape
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report